Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“KEYNOTE-427 final results (61 months follow-up) in Annals of Oncology: pembrolizumab monotherapy in first-line advanced ccRCC and nccRCC – ORR 36.4% and 26.7%, respectively.
PD-L1 CPS and T-cell-inflamed GEP associated with outcomes in both cohorts.
Baseline ctDNA positivity linked to shorter OS (30.5 vs 53.7 months).”
Title: Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study
Authors: D.F. McDermott, S. Signoretti, J.-L. Lee, F. Donskov, S.S. Tykodi, P. Tomczak, G.A. Bjarnason, J.M.G. Larkin, M.D. Kochenderfer, R.A. Gafanov, R. Cristescu, J. Markensohn, M. Nebozhyn, Y. Zhang, X. Peng, K. Rodriguez-Lopez, J. Burgents, R.F. Perini, M.B. Atkins
Other articles about renal cell carcinoma on OncoDaily.